FANGZHOU JIANKE

6086
1.0201.49% ( +0.015 )
Delay Closed: Nov 16, 16:08:11

Overview

FANGZHOU JIANKE (6086)

Fangzhou Inc. provides online chronic disease management services in China. It operates through four segments: Online Retail Pharmacy Services; Comprehensive Me...

Open
0.990
High
1.025
Low
0.975
Prev. Close
1.005
Volume
125.50K
Turnover
125.55K
Avg Price
1.000
Bid/Ask Ratio
66.67%
Amplitude
4.98%
52wk High
4.330
Volume Ratio
0.35
Turnover Ratio
0.01%
52wk Low
0.625
HK Mkt Cap
1.41B
Market CapHKD
1.41B
P/ETTM
148.69
P/EDynamic
68.92
P/EStatic
--
EPSTTM
0.0069
EPSDynamic
0.0148
EPSStatic
--
BVPS
0.25
P/B
4.14
HK Shares
1.39B
Dividend YieldTTM
--
DividendTTM
--
Shares
1.39B
Min lot size
500
Currency
HKD

FANGZHOU JIANKE Analyst Rating

View more

Forecast & Rating

Sep 3, 2026
Price forecast
HK$6.00488.35%
Forecast & RatingStrong buy
1analysts
  • Strong buy100.00%
  • Buy0.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Jul, 3

    Fangzhou Inc. surged 19.7% today, driven by market recognition of its AI-powered chronic disease management platform and recent profitability milestone. The stock hit an afternoon high of HK$0.840 and closed at HK$0.790, far above a morning low of HK$0.660, yet the YTD decline stands at 64.6%, with the current price 85% below its 52-week high of HK$5.26 and below the 20-day MA of HK$0.851. Q4 revenue jumped 53.5% YoY to HK$1.13 billion, while net loss narrowed 98% to just HK$0.36 million, nearing breakeven, though net profit margin remained negative at -0.03%. However, the company recently raised approximately HK$144 million through a share placement for AI platform expansion, which may cap further upside amid dilution concerns.

News